Current Situation in the Development of a Preventive HIV Vaccine

Overview

Journal Enferm Infecc Microbiol Clin

Specialty Infectious Diseases

Date 2024 Apr 15

PMID 38620211

Authors

Jose Alcami

Joan Joseph Munne

Maria Angeles Munoz-Fernandez

Mariano Esteban

Affiliations

Soon will be listed here.

Abstract

The uncontrolled progression of the aids epidemic has made the development of an efficacious human immunodeficiency virus (HIV) vaccine a major objective of scientific research. No effective preventive vaccine against HIV is currently available and sterilizing immunity has not yet been achieved in animal models. This review analyses the major challenges in developing an aids vaccine, in particular the mechanisms involved in viral escape from the immune response, and summarizes the results obtained with the different prototypes of therapeutic and preventive vaccines. Finally, social, economic and healthcare aspects of research into HIV vaccines and current controversies regarding the development of clinical trials are discussed.

References

Rosenberg E, Altfeld M, Poon S, Phillips M, Wilkes B, Eldridge R . Immune control of HIV-1 after early treatment of acute infection. Nature. 2000; 407(6803):523-6. DOI: 10.1038/35035103. View

Gherardi M, Ramirez J, Esteban M . IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol. 2003; 84(Pt 8):1961-1972. DOI: 10.1099/vir.0.19120-0. View

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

Nabel G, Sullivan N . Antibodies and resistance to natural HIV infection. N Engl J Med. 2000; 343(17):1263-5. DOI: 10.1056/NEJM200010263431711. View

Douek D, Brenchley J, Betts M, Ambrozak D, Hill B, Okamoto Y . HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417(6884):95-8. DOI: 10.1038/417095a. View

Deacon N, Tsykin A, Solomon A, Smith K, Hooker D, McPhee D . Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995; 270(5238):988-91. DOI: 10.1126/science.270.5238.988. View

Verrier F, Burda S, Belshe R, Duliege A, Excler J, Klein M . A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol. 2000; 74(21):10025-33. PMC: 102041. DOI: 10.1128/jvi.74.21.10025-10033.2000. View

Haase A . Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999; 17:625-56. DOI: 10.1146/annurev.immunol.17.1.625. View

Greenough T, Sullivan J, Desrosiers R . Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med. 1999; 340(3):236-7. DOI: 10.1056/NEJM199901213400314. View

10.

Stahl-Hennig C, Steinman R, Tenner-Racz K, Pope M, Stolte N, Matz-Rensing K . Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 1999; 285(5431):1261-5. DOI: 10.1126/science.285.5431.1261. View

11.

Hanke T, Samuel R, Blanchard T, Neumann V, Allen T, Boyson J . Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol. 1999; 73(9):7524-32. PMC: 104279. DOI: 10.1128/JVI.73.9.7524-7532.1999. View

12.

Sung M, Simon R . Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides. J Comput Biol. 2004; 11(1):125-45. DOI: 10.1089/106652704773416920. View

13.

OConnor D, Allen T, Vogel T, Jing P, DeSouza I, Dodds E . Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med. 2002; 8(5):493-9. DOI: 10.1038/nm0502-493. View

14.

Evans T, Keefer M, Weinhold K, Wolff M, Montefiori D, Gorse G . A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 1999; 180(2):290-8. DOI: 10.1086/314895. View

15.

Mascola J, Stiegler G, Vancott T, Katinger H, Carpenter C, Hanson C . Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6(2):207-10. DOI: 10.1038/72318. View

16.

Barouch D, Craiu A, Kuroda M, Schmitz J, Zheng X, Santra S . Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A. 2000; 97(8):4192-7. PMC: 18194. DOI: 10.1073/pnas.050417697. View

17.

Burton D, Desrosiers R, Doms R, Koff W, Kwong P, Moore J . HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004; 5(3):233-6. DOI: 10.1038/ni0304-233. View

18.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

19.

Zinkernagel R, Doherty P . MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol. 1979; 27:51-177. DOI: 10.1016/s0065-2776(08)60262-x. View

20.

Kwong P, Doyle M, Casper D, Cicala C, Leavitt S, Majeed S . HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002; 420(6916):678-82. DOI: 10.1038/nature01188. View